Kane Biotech Announces New Agreement with FreeMind Group
July 16 2019 - 6:55AM
Kane Biotech Inc. (TSX-V:KNE), (the “Corporation” or “Kane
Biotech”), a biotechnology company engaged in the research,
development and commercialization of technologies and products that
prevent and remove microbial biofilms, today announced that it has
signed an agreement with FreeMind Group, a premier international
consulting firm dedicated to securing non-dilutive funding from
various public and private sources for its clients. The FreeMind
process begins with the strategic assessment of potential funding
opportunities, includes the grant production process and
submission, and ends with approval and the subsequent funding
award.
Ray Dupuis, Chief Financial Officer of Kane Biotech, stated, “A
key component of our financial strategy includes securing
non-dilutive funding from a variety of sources, and our newly
established agreement with FreeMind Group will support this
strategy. Given FreeMind’s great success to date in securing
funding for its clients, I am very optimistic in their ability to
assist Kane during this pivotal time. We believe our work in
addressing the key issue of biofilms in a number of areas,
including the wound care space, will be of great interest to
potential funders. Non-dilutive funding will further our progress
with R&D in the Animal and Human Health sectors and will also
assist with our continued exploration of other potential uses for
our proprietary technology in a number of new sectors.”
About Kane Biotech
Kane Biotech is a biotechnology company engaged in the research,
development and commercialization of technologies and products that
prevent and remove microbial biofilms. The Corporation has a
portfolio of biotechnologies, intellectual property (56 patents and
patents pending, trade secrets and trademarks) and products
developed by the Corporation’s own biofilm research expertise and
acquired from leading research institutions. StrixNB(TM),
DispersinB(R), Aledex(R), bluestem(TM), AloSera(TM), coactiv+(TM)
and Kane(R) are trademarks of Kane Biotech Inc. The Corporation is
listed on the TSX Venture Exchange under the symbol "KNE".
About FreeMind Group
The FreeMind Group is a premier international consulting firm
that specializes in assisting life science organizations secure
non-dilutive funding from US federal agencies, such as the National
Institutes of Health and Department of Defense, and private
foundations. Established in 1999, FreeMind is the largest
consulting group of its kind and works with academics and research
institutions as well as industry from all around the world.
Services provided by the FreeMind Group include strategic
assessment of available funding opportunities, assistance with
application preparation, and reward negotiation. FreeMind’s proven
long-term, multi-submission, strategic approach has garnered its
clients over 1.5 billion dollars to date.
For more information, please visit
www.kanebiotech.com, or contact:
Marc EdwardsChief Executive OfficerKane Biotech
Inc.
+1 (514)
910-6991
medwards@kanebiotech.com
Joe Green US. Investor Relations Edison Inc.+1 (646) 653-7030
jgreen@edisongroup.com
Laine YonkerUS. Investor RelationsEdison Inc. +1 (646) 653
7035
lyonker@edisongroup.com
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
Caution Regarding Forward-Looking
Information
This press release contains certain statements regarding Kane
Biotech Inc. that constitute forward-looking information under
applicable securities law. These statements reflect management’s
current beliefs and are based on information currently available to
management. Certain material factors or assumptions are applied in
making forward-looking statements, and actual results may differ
materially from those expressed or implied in such statements.
These risks and uncertainties include, but are not limited to,
risks relating to the Company’s: (a) financial condition, including
lack of significant revenues to date and reliance on equity and
other financing; (b) business, including its early stage of
development, government regulation, market acceptance for its
products, rapid technological change and dependence on key
personnel; (c) intellectual property including the ability of the
Company to protect its intellectual property and dependence on its
strategic partners; and (d) capital structure, including its lack
of dividends on its common shares, volatility of the market price
of its common shares and public company costs. Further information
about these and other risks and uncertainties can be found in the
disclosure documents filed by the Company with applicable
securities regulatory authorities, available at www.sedar.com. The
Company cautions that the foregoing list of factors that may affect
future results is not exhaustive.
Kane Biotech (TSXV:KNE)
Historical Stock Chart
From Aug 2024 to Sep 2024
Kane Biotech (TSXV:KNE)
Historical Stock Chart
From Sep 2023 to Sep 2024